Effects of general anesthesia with or without epidural block on tumor metastasis and mechanisms

  • Authors:
    • Bin Yang
    • Feng Qian
    • Wenjia Li
    • Yang Li
    • Yangdong Han
  • View Affiliations

  • Published online on: January 26, 2018     https://doi.org/10.3892/ol.2018.7870
  • Pages: 4662-4668
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

The present study aimed to assess whether different anesthesia methods (general anesthesia and general anesthesia combined with epidural block) were associated with tumor metastasis during the perioperative period and the possible molecular mechanisms of tumor metastasis. A rat hepatoma tumor xenograft model was constructed via the subcutaneous injection of Morris hepatoma 3924A cells into the upper axillary fossa. General anesthesia and general anesthesia combined with epidural block prior to hepatectomy were conducted on tumor‑bearing rats. The average numbers of metastatic nodules on the lung surface were calculated in the different groups and the presence of abdominal lymph node metastases, rate of malignant ascites and abdominal wall‑implanted nodules were recorded. Blood samples were collected from the orbits of rats immediately prior to surgery and at 2, 7 and 30 days following surgery. Plasma levels of interferon‑γ, transforming growth factor‑α and vascular endothelial growth factor (VEGF) were measured. Finally, the expression of phosphorylated signal transducer and activator of transcription‑3 and phosphorylated VEGF were measured by western blot analysis. The results of this analysis demonstrated that tumor metastasis was greatly suppressed when the rats underwent general anesthesia combined with epidural block prior to hepatectomy, compared with general anesthesia alone. The results of cytokine quantification and western blot analysis revealed that the anti‑metastatic effect of general anesthesia combined with epidural block may have been mediated by inhibition of STAT3 and the relevant cytokines.

References

1 

Zhu RX, Seto WK, Lai CL and Yuen MF: Epidemiology of hepatocellular carcinoma in the Asia-pacific region. Gut Liver. 10:332–339. 2016. View Article : Google Scholar : PubMed/NCBI

2 

Llovet JM: Updated treatment approach to hepatocellular carcinoma. J Gastroenterol. 40:225–235. 2005. View Article : Google Scholar : PubMed/NCBI

3 

Buggy DJ and Smith G: Epidural anesthesia and analgesia: Better outcome after major surgery? Growing evidence suggests so. BMJ. 319:530–531. 1999. View Article : Google Scholar : PubMed/NCBI

4 

Ogawa K, Hirai M, Katsube T, Murayama M, Hamaguchi K, Shimakawa T, Naritake Y, Hosokawa T and Kajiwara T: Suppression of cellular immunity by surgical stress. Surgery. 127:329–336. 2000. View Article : Google Scholar : PubMed/NCBI

5 

Ben-Eliyahu S: The price of anticancer intervention. Does surgery promote metastasis? Lancet Oncol. 3:578–579. 2002.PubMed/NCBI

6 

Ben-Eliyahu S, Page GG, Yirmiya R and Shakhar G: Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Int J Cancer. 80:880–888. 1999. View Article : Google Scholar : PubMed/NCBI

7 

Deiner S and Silverstein JH: Long-term outcomes in elderly surgical patients. Mt Sinai J Med. 79:95–106. 2012. View Article : Google Scholar : PubMed/NCBI

8 

Deflandre E and Lacroix S: It is time for anesthetists to act as perioperative physicians. Minerva Anestesiol. 82:257–258. 2016.PubMed/NCBI

9 

Martin TA, Ye L, Sanders AJ, Lane J and Jiang WG: Cancer invasion and metastasis: Molecular and cellular perspectiveMetastatic Cancer Clinical Biological Perspectives 2013. Jandial R: Landes Bioscience; Austin, TX: pp. 135–168. 2013

10 

Tsuchiya Y, Sawada S, Yoshioka I, Ohashi Y, Matsuo M, Harimaya Y, Tsukada K and Saiki I: Increased surgical stress promotes tumor metastasis. Surgery. 133:547–555. 2003. View Article : Google Scholar : PubMed/NCBI

11 

Ucuzian AA, Gassman AA, East AT and Greisler HP: Molecular mediators of angiogenesis. J Burn Care Res. 31:158–175. 2010. View Article : Google Scholar : PubMed/NCBI

12 

Distler JH, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S and Distler O: Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med. 47:149–161. 2003.PubMed/NCBI

13 

Simons M: Integrative signaling in angiogenesis. Mol Cell Biochem. 264:99–102. 2004. View Article : Google Scholar : PubMed/NCBI

14 

Chen Z and Han ZC: STAT3: A critical transcription activator in angiogenesis. Med Res Rev. 28:185–200. 2008. View Article : Google Scholar : PubMed/NCBI

15 

Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT and De Bruijn EA: Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 56:549–580. 2004. View Article : Google Scholar : PubMed/NCBI

16 

Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS and Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219:983–985. 1983. View Article : Google Scholar : PubMed/NCBI

17 

Leung DW, Cachianes G, Kuang WJ, Goeddel DV and Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1306–1309. 1989. View Article : Google Scholar : PubMed/NCBI

18 

Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R and Huang S: Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene. 23:3550–3560. 2004. View Article : Google Scholar : PubMed/NCBI

19 

Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE, Xie K, Sawaya R and Huang S: Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res. 66:3188–3196. 2006. View Article : Google Scholar : PubMed/NCBI

20 

Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E and Sessler DI: Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology. 105:660–664. 2006. View Article : Google Scholar : PubMed/NCBI

21 

Bauer M, Rensing H and Ziegenfuss T: Anesthesia and perioperative immune function. Anaesthesist. 47:538–556. 1998.(In German). View Article : Google Scholar : PubMed/NCBI

22 

Borsook D, George E, Kussman B and Becerra L: Anesthesia and perioperative stress: Consequences on neural networks and postoperative behaviors. Prog Neurobiol. 92:601–612. 2010. View Article : Google Scholar : PubMed/NCBI

23 

Marshall L, Khan AH and Buggy DJ: Can anaesthetic and analgesic techniques for cancer surgery affect cancer recurrence and metastasis? Curr Anesthesiology Rep. 5:190–202. 2015. View Article : Google Scholar

24 

Vahabi S and Eatemadi A: Effects of anesthetic and analgesic techniques on cancer metastasis. Biomed Pharmacother. 87:1–7. 2017. View Article : Google Scholar : PubMed/NCBI

25 

Ogren SO and Holm AC: Test-specific effects of the 5-HT reuptake inhibitors alaproclate and zimelidine on pain sensitivity and morphine analgesia. J Neural Transm. 47:253–271. 1980. View Article : Google Scholar : PubMed/NCBI

26 

Sacerdote P, Bianchi M, Gaspani L, Manfredi B, Maucione A, Terno G, Ammatuna M and Panerai AE: The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg. 90:1411–1414. 2000. View Article : Google Scholar : PubMed/NCBI

27 

Yeager MP, Colacchio TA, Yu CT, Hildebrandt L, Howell AL, Weiss J and Guyre PM: Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology. 83:500–508. 1995. View Article : Google Scholar : PubMed/NCBI

28 

Sasamura T, Nakamura S, Iida Y, Fujii H, Murata J, Saiki I, Nojima H and Kuraishi Y: Morphine analgesia suppresses tumor growth and metastasis in a mouse model of cancer pain produced by orthotopic tumor inoculation. Eur J Pharmacol. 441:185–191. 2002. View Article : Google Scholar : PubMed/NCBI

29 

Ash SA and Buggy DJ: Does regional anaesthesia and analgesia or opioid analgesia influence recurrence after primary cancer surgery? An update of available evidence. Best Pract Res Clin Anaesthesiol. 27:441–456. 2013. View Article : Google Scholar : PubMed/NCBI

30 

Gupta K, Kshirsagar S, Chang L, Schwartz R, Law PY, Yee D and Hebbel RP: Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res. 62:4491–4498. 2002.PubMed/NCBI

31 

Cao LH, Li HT, Lin WQ, Tan HY, Xie L, Zhong ZJ and Zhou JH: Morphine, a potential antagonist of cisplatin cytotoxicity, inhibits cisplatin-induced apoptosis and suppression of tumor growth in nasopharyngeal carcinoma xenografts. Sci Rep. 6:187062016. View Article : Google Scholar : PubMed/NCBI

32 

Rahaman SO, Vogelbaum MA and Haque SJ: Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: Involvement of IL-13Ralpha2. Cancer Res. 65:2956–2963. 2005. View Article : Google Scholar : PubMed/NCBI

33 

Lamprecht B, Kreher S, Anagnostopoulos I, Jöhrens K, Monteleone G, Jundt F, Stein H, Janz M, Dörken B and Mathas S: Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood. 112:3339–3347. 2008. View Article : Google Scholar : PubMed/NCBI

34 

Yue P, Zhang X, Paladino D, Sengupta B, Ahmad S, Holloway RW, Ingersoll SB and Turkson J: Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells. Oncogene. 31:2309–2322. 2012. View Article : Google Scholar : PubMed/NCBI

35 

Sordella R, Bell DW, Haber DA and Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 305:1163–1167. 2004. View Article : Google Scholar : PubMed/NCBI

36 

Ali SM, Wang K, Johnson A, Rodriguez AA, Elvin JA, Vergilio JA, Suh JH, Chumsri S, Morosini D, Yelensky R, et al: Abstract P6-03-02: EGFR genomic alterations in 5,605 cases of refractory and metastatic breast cancer. Cancer Res. 76 Suppl 4:P6–03-02. 2016. View Article : Google Scholar

37 

Milagre CS, Gopinathan G, Everitt G, Thompson RG, Kulbe H, Zhong H, Hollingsworth RE, Grose R, Bowtell DD, Hochhauser D and Balkwill FR: Adaptive upregulation of EGFR limits attenuation of tumor growth by neutralizing IL6 antibodies, with implications for combined therapy in ovarian cancer. Cancer Res. 75:1255–1264. 2015. View Article : Google Scholar : PubMed/NCBI

38 

Falchook GS, Naing A, Wheler JJ, Tsimberidou AM, Zinner R, Hong DS, Fu S, Piha-Paul SA, Janku F, Hess KR, et al: Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience. 1:540–549. 2014. View Article : Google Scholar : PubMed/NCBI

39 

Engilbertsson H, Aaltonen KE, Björnsson S, Kristmundsson T, Patschan O, Rydén L and Gudjonsson S: Transurethral bladder tumor resection can cause seeding of cancer cells into the bloodstream. J Urol. 193:53–57. 2015. View Article : Google Scholar : PubMed/NCBI

40 

Zhang W, Liu JN and Tan XY: Vaccination with xenogeneic tumor endothelial proteins isolated in situ inhibits tumor angiogenesis and spontaneous metastasis. Int J Cancer. 125:124–132. 2009. View Article : Google Scholar : PubMed/NCBI

41 

Ramírez MF, Huitink JM and Cata JP: Perioperative clinical interventions that modify the immune response in cancer patients. Open J Anesthesiology. 3:133–139. 2013. View Article : Google Scholar

42 

Wang X, Cao W, Mo M, Wang W, Wu H and Wang J: VEGF and cortactin expression are independent predictors of tumor recurrence following curative resection of gastric cancer. J Surg Oncol. 102:325–330. 2010. View Article : Google Scholar : PubMed/NCBI

43 

Chavira E, Wilson M, Assaf SA, Ingles SA, Llanes A and Chmait R: Anti-angiogenic state in twin-twin transfusion syndrome ameliorated after laser surgery. Ame J Obst Gynecology. 206:S52. 2012. View Article : Google Scholar

44 

Zielinski CE, Mele F, Aschenbrenner D, Jarrossay D, Ronchi F, Gattorno M, Monticelli S, Lanzavecchia A and Sallusto F: Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β. Nature. 484:514–518. 2012. View Article : Google Scholar : PubMed/NCBI

45 

O'Connell J, Bennett MW, O'Sullivan GC, Collins JK and Shanahan F: The Fas counterattack: Cancer as a site of immune privilege. Immunol Today. 20:46–52. 1999. View Article : Google Scholar : PubMed/NCBI

46 

Müller CB, De Bastiani MA, Becker M, França FS, Branco MA, Castro MA and Klamt F: Potential crosstalk between cofilin-1 and EGFR pathways in cisplatin resistance of non-small-cell lung cancer. Oncotarget. 6:3531–3539. 2015. View Article : Google Scholar : PubMed/NCBI

47 

Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B and Bromberg JF: Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest. 117:3846–3856. 2007. View Article : Google Scholar : PubMed/NCBI

48 

Abbott BD, Buckalew AR, DeVito MJ, Ross D, Bryant PL and Schmid JE: EGF and TGF-alpha expression influence the developmental toxicity of TCDD: Dose response and AhR phenotype in EGF, TGF-alpha, and EGF + TGF-alpha knockout mice. Toxicol Sci. 71:84–95. 2003. View Article : Google Scholar : PubMed/NCBI

49 

Weaver CT, Harrington LE, Mangan PR, Gavrieli M and Murphy KM: Thl7: An effector CD4 T cell lineage with regulatory T cell ties. Immunity. 24:677–688. 2006. View Article : Google Scholar : PubMed/NCBI

50 

Sen B, Saigal B, Parikh N, Gallick G and Johnson FM: Sustained src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer Res. 69:1958–1965. 2009. View Article : Google Scholar : PubMed/NCBI

51 

Juergens RA and Brahmer JR: Adjuvant treatment in non-small cell lung cancer: Where are we now? J Natl Compr Canc Netw. 4:595–600. 2006. View Article : Google Scholar : PubMed/NCBI

52 

Smith RA and Glynn TJ: Epidemiology of lung cancer. Radiol Clin North Am. 38:453–470. 2000. View Article : Google Scholar : PubMed/NCBI

53 

Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol. 18:2354–2362. 2000. View Article : Google Scholar : PubMed/NCBI

54 

Herrera B, van Dinther M, Ten Dijke P and Inman GJ: Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation. Cancer Res. 69:9254–9262. 2009. View Article : Google Scholar : PubMed/NCBI

55 

Jean GW and Shah SR: Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy. 28:742–754. 2008. View Article : Google Scholar : PubMed/NCBI

56 

Siveen KS, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, Tan BK, Sethi G and Bishayee A: Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors. Biochim Biophys Acta. 1845:136–154. 2014.PubMed/NCBI

57 

Song JI and Grandis JR: STAT signaling in head and neck cancer. Oncogene. 19:2489–2495. 2000. View Article : Google Scholar : PubMed/NCBI

58 

Morlacchi P, Robertson FM, Klostergaard J and McMurray JS: Targeting SH2 domains in breast cancer. Future Med Chem. 6:1909–1926. 2014. View Article : Google Scholar : PubMed/NCBI

59 

Lapeire L, Hendrix A, Lambein K, Van Bockstal M, Braems G, Van Den Broecke R, Limame R, Mestdagh P, Vandesompele J, Vanhove C, et al: Cancer-associated adipose tissue promotes breast cancer progression by paracrine oncostatin M and Jak/STAT3 signaling. Cancer Res. 74:6806–6819. 2014. View Article : Google Scholar : PubMed/NCBI

60 

Penuel E, Kapp AV, Do A, Tam R, Sumiyoshi T, Marathe C, Sa S, Peale F, Lackner M, Holden S, et al: Biomarker evaluation in a randomized phase 2 study of MEHD7945A (MEHD) versus cetuximab (Cet) in ≥2 line recurrent/metastatic (R/M) squamous cell carcinomas of the head and neck (SCCHN) [MEHGAN]. Cancer Res. 75 Suppl 15:15532015. View Article : Google Scholar

61 

Luwor RB, Baradaran B, Taylor LE, Iaria J, Nheu TV, Amiry N, Hovens CM, Wang B, Kaye AH and Zhu HJ: Targeting Stat3 and Smad7 to restore TGF-β cytostatic regulation of tumor cells in vitro and in vivo. Oncogene. 32:2433–2441. 2013. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

April 2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yang, B., Qian, F., Li, W., Li, Y., & Han, Y. (2018). Effects of general anesthesia with or without epidural block on tumor metastasis and mechanisms. Oncology Letters, 15, 4662-4668. https://doi.org/10.3892/ol.2018.7870
MLA
Yang, B., Qian, F., Li, W., Li, Y., Han, Y."Effects of general anesthesia with or without epidural block on tumor metastasis and mechanisms". Oncology Letters 15.4 (2018): 4662-4668.
Chicago
Yang, B., Qian, F., Li, W., Li, Y., Han, Y."Effects of general anesthesia with or without epidural block on tumor metastasis and mechanisms". Oncology Letters 15, no. 4 (2018): 4662-4668. https://doi.org/10.3892/ol.2018.7870